Hair Shedding on GLP-1 Medications: What the Evidence Actually Shows
Hair Shedding on GLP-1 Medications:
What the Evidence Actually Shows
And What It Doesn't.
The calls started this year and they all sound the same: Ozempic, Wegovy, Mounjaro or Zepbound, the weight is coming off, everything is working, and the hair is coming out. The shedding is real and it is measurable. What almost nobody says out loud is that the strongest evidence points at the weight loss rather than at the drug — and that changes what you do about it.
Hair shedding on a GLP-1 medication is real and measurable. The best-designed study so far — a target trial emulation in adults with type 2 diabetes — found alopecia at 6.53 per 1,000 person-years on GLP-1s against 3.89 on a weight-neutral comparator drug.[2] Almost all of it looks like telogen effluvium, the reversible kind, and there is no strong evidence of permanent damage to the follicle.[4] The mechanism most of the evidence points to is the rapid weight loss, not the drug acting on the hair. Rapid weight loss has always done this: after bariatric surgery, with no GLP-1 involved, pooled hair loss runs at 57%.[6] Shedding typically starts two to three months in and improves within three to six months once weight stabilizes.[4] None of that is a reason to stop a prescribed medication on your own.
- Which drugs this covers — Ozempic, Wegovy, Mounjaro, Zepbound
- What the shedding on a GLP-1 actually is
- What the studies found
- The drug, or the weight loss?
- Why women report it far more often
- When it starts, and when it stops
- The micronutrient picture
- What actually helps
- Why stopping the medication is the wrong first move
- When it isn't a temporary shed
- Compared with other causes of shedding
- What happens at a scalp evaluation
- The evidence behind this article, graded
- Frequently asked questions
Which Drugs This Covers — Ozempic, Wegovy, Mounjaro and Zepbound
People search for the brand name, not the drug class, so it is worth being plain about which is which. Everything in this article applies to all of them.
- Semaglutide — sold as Ozempic (type 2 diabetes), Wegovy (weight loss) and Rybelsus (oral, for diabetes).
- Tirzepatide — sold as Mounjaro (type 2 diabetes) and Zepbound (weight loss and obstructive sleep apnea).
- Dulaglutide (Trulicity) and liraglutide (Victoza, Saxenda) are older drugs in the same family.
One point of precision that most articles skip: tirzepatide is not a pure GLP-1 receptor agonist. It is a dual agonist, acting on both GLP-1 and GIP receptors. The studies below group it with the GLP-1 drugs, as the published literature does, but Mounjaro and Zepbound are not pharmacologically identical to Ozempic and Wegovy, and the hair-loss signal reported for them is not automatically transferable.
What the Shedding on a GLP-1 Actually Is
Almost every case described in the literature looks like telogen effluvium: a diffuse shed, spread across the whole scalp rather than concentrated in a pattern, in which an unusual number of hairs are pushed out of their growing phase and into their resting phase at once.[4][5]
That resting phase lasts around three to five months, and the hair stays anchored in the follicle throughout it before releasing.[8] This is why the shedding never coincides with the thing that caused it: hair loss generally becomes visible two to three months after the trigger.[8] By the time you see hair in the drain, the cause is months behind you.
This matters because telogen effluvium is the reversible category. The follicle is not destroyed; it is interrupted. A 2026 systematic review states that patients can be reassured there is no strong evidence of permanent follicular damage associated with these drugs, and that the reported cases resemble telogen effluvium, which is typically self-limited and reversible.[4]
Normal daily shedding is 50 to 100 hairs. When something pushes a large share of follicles into rest together, the count rises well above that, and fullness usually returns within six to nine months once the trigger passes.[1]
What the Studies Found
Four separate lines of evidence now exist, and they were published close enough together that most of what is written about this subject predates them. They are not equally strong, and it is worth being clear about which is which.
1. The strongest design: a target trial emulation
Published in The BMJ in 2026, this study used health-system records to imitate the structure of a randomized trial, and — crucially — compared GLP-1 users against people taking other diabetes drugs rather than against untreated controls. That removes diabetes itself, and the fact of being treated, from the comparison.[2]
- Against SGLT-2 inhibitors (12,004 vs 15,221 patients): alopecia 6.91 vs 5.04 per 1,000 person-years — a 37% higher risk.[2]
- Against DPP-4 inhibitors (11,964 vs 11,238 patients): 6.53 vs 3.89 per 1,000 person-years — a 68% higher risk.[2]
- For non-scarring alopecia specifically, the increases were 53% and 72% against the two comparators.[2]
2. A large matched cohort
A research letter reporting a cohort drawn from 67 US healthcare organizations, matching GLP-1 users against controls, found that at twelve months the adjusted odds of telogen effluvium rose 1.76-fold and androgenetic alopecia 1.64-fold, with non-scarring hair loss overall at 1.40 (all P<.001).[3] Two details of that paper are worth carrying: at six months the telogen effluvium result was not statistically significant, and alopecia areata was consistently higher in the control group, which argues against any effect on autoimmune hair loss.[3] Hair-loss outcomes in this study were identified from diagnostic codes rather than by examining anyone.[3]
3. What the drug trials reported
A systematic review of 24 studies put the incidence at 6.0 cases per 1,000 patient-years on GLP-1 therapy against 0.8 per 1,000 patient-years on placebo — a risk ratio of 3.40, though with a wide confidence interval of 1.18 to 9.81 that reflects how few controlled trials have measured this properly.[4] In tirzepatide (Mounjaro and Zepbound) obesity trials, alopecia was reported by 5.4% (119/2,183) of treated participants against 0.9% (22/2,221) on placebo. High-dose oral semaglutide — the same molecule as Ozempic and Wegovy — showed 7% (23/334) against 3% (9/333), while the lower doses showed almost nothing — which suggests the effect is dose-related.[4]
A 2026 meta-analysis restricted to interventional studies — nine of them, seven randomized controlled trials, 4,114 GLP-1 users — put the pooled risk ratio at 3.25 (95% CI 1.44–7.36), and higher still in the trials conducted in overweight and obesity at 3.59 (95% CI 2.10–6.12).[17] Randomized data cannot be confounded by who chooses to take these drugs, which is the weakness every cohort study here carries. That the obesity trials show the larger effect is consistent with the weight-loss explanation below.
4. The meta-analysis, and what it actually pooled
A 2026 systematic review and meta-analysis screened 1,847 records, included 17 studies covering 1,091,743 patient-exposures, and concluded that GLP-1 receptor agonists carry a 40% increased risk of non-scarring alopecia, “primarily mediated by weight loss-induced micronutrient deficiency.”[5] It also reported a finding nobody expected: 58% of patients with central centrifugal cicatricial alopecia improved on GLP-1 therapy.[5]
Its headline figure is OR 1.40 (95% CI 1.33–1.48) — but the paper states that estimate was pooled from three cohort studies, not from all seventeen.[5] The telogen effluvium and androgenetic alopecia figures it reports are the same numbers published by the matched cohort described above, so they are not independent confirmation of it.[3] And a large share of that million-plus patient-exposure total comes from that single cohort. The meta-analysis is real and useful. It is not seventeen studies all independently finding the same thing, and it should not be quoted as though it were.
Every one of them describes an association. None of these studies randomized anyone to a drug versus the same rate of weight loss without it, which is the only design that could fully separate the two. Several identify hair loss from diagnostic coding, which records who sought care rather than who shed. The BMJ authors note directly that they could not assess severity, extent, duration or reversibility, and could not rule out unmeasured confounding.[2]
The Drug, or the Weight Loss?
This is the question almost nothing written about GLP-1 hair loss answers directly, and the evidence is clearer than the silence suggests.
The meta-analysis states its reading in one sentence: the increased risk is “primarily mediated by weight loss-induced micronutrient deficiency.”[5] The BMJ investigators reach for the same explanation. Their paper calls rapid or substantial weight loss “a well established trigger of telogen effluvium, a form of diffuse, non-scarring hair shedding,” and adds that caloric restriction “may also contribute to physiological stress and micronutrient deficiencies (for example, iron, zinc, biotin), which can disrupt the hair growth cycle.”[2] Neither group is describing a drug that attacks the follicle. They are describing a drug that produces rapid weight loss extremely effectively — and rapid weight loss has always done this.
The detail inside the BMJ study that makes the case. Its two comparator drugs differ in exactly one relevant way. SGLT-2 inhibitors cause modest weight loss — about 1.7 kg more than DPP-4 inhibitors at low dose and 1.9 kg more at high dose, in pooled trial data — while DPP-4 inhibitors are weight-neutral, neither causing loss nor gain.[9] And the gap in hair loss tracks that difference: GLP-1 users had 37% more alopecia than the comparator that also causes some weight loss, and 68% more than the comparator that causes none.[2] The more weight the comparison drug takes off, the smaller the difference. The counter-evidence, stated honestly: these three drug classes differ in more than their weight effects, the study was not designed to test this, and its authors do not make this argument. It is a pattern consistent with the mechanism, not proof of it.
The same two molecules are sold at two doses, for two purposes, and their labels do not say the same thing. Semaglutide at diabetes doses is Ozempic; at obesity doses it is Wegovy. Tirzepatide at diabetes doses is Mounjaro; at obesity doses it is Zepbound. Ozempic and Mounjaro list alopecia only under Postmarketing Experience, with no clinical-trial incidence rate at all.[15] Wegovy and Zepbound report it as a trial adverse reaction — Wegovy at 3% against 1% on placebo, rising to 5.8% at the 7.2 mg dose; Zepbound at 4 to 5% across doses against 1% on placebo.[13][14] Same molecules. What changes is how much weight comes off. Both obesity labels state it outright: hair loss adverse reactions in treated patients “were associated with weight reduction.”[13][14] The honest limit: the diabetes and obesity programs enrolled different populations, so this is not a controlled comparison either — but it is the regulator attributing the effect to weight reduction, not a commentator.
Two further observations point the same way. Bariatric surgery — rapid weight loss achieved surgically, with no GLP-1 anywhere in the picture — produces pooled hair loss of 57% (95% CI 42–71%) across 18 studies and 2,538 patients.[6] And in the patient survey, shedding was most pronounced in the people who lost the most: 57.0% of those losing 40 pounds or more reported both shedding and thinning together.[7] A direct drug toxicity would not care how much weight came off.
Those two figures in the paragraph above are unrelated and it is easy to run them together. One is a pooled incidence across bariatric surgery patients; the other is a subgroup of a single survey — the share of heavy losers reporting both symptoms at once. The resemblance is a coincidence.
Why Women Report It Far More Often
The sex difference in the trial data is not subtle. The prescribing information reports alopecia in 7.1% of women against 0.5% of men on Zepbound, and in 8.4% of women against 0.2% of men on Wegovy at its 7.2 mg dose.[13][14] The 2026 systematic review reports the same Zepbound split.[4]
The first explanation the authors give is not biological. They note that women are generally more likely to notice hair loss and to seek medical attention for it, which may especially affect reporting rates in pharmacovigilance databases.[4] Some portion of a fourteen-fold gap is almost certainly who reports, not who sheds.
Beyond that, there is a real difference in how visible a shed is. Women who already have early androgenetic thinning — often undiagnosed, because female pattern loss widens the part rather than creating a bald spot — have less density in reserve, so a diffuse shed on top of it shows immediately. Androgenetic alopecia diagnoses did rise alongside telogen effluvium in the cohort data, and the authors of that study allow that the rise may reflect drug effects, metabolic effects or surveillance — people being looked at more closely.[3]
When It Starts, and When It Stops
The timing is the most consistently reported part of this picture, and it is the part that reassures people most.
Shedding begins with a delay of roughly two to three months after starting treatment.[4] In the survey data, 42% of those reporting shedding noticed it within the first one to three months of therapy.[7] That delay is not a quirk — it is the resting phase running its course. The hairs that come out in month three were committed to falling in month one.
Recovery follows the same clock in reverse. The systematic review reports that improvement is generally seen within three to six months following stabilization of weight.[4] The bariatric literature gives a longer view of the same pattern: across studies, reported hair loss fell from 58% within the first year to 35% after twelve months or more,[6] and in one study within that review, onset averaged 3.4 months and resolution around 9 months.[6]
The practical reading: the clock starts when the weight stabilizes, not when the shedding starts. Someone still losing rapidly at month eight has not failed to recover — the trigger is still running.
The Micronutrient Picture
If the mechanism is weight-loss-mediated, the nutritional detail is where it becomes actionable. The bariatric meta-analysis is the most useful source here, because it measured blood work against hair loss in the same patients — and its results are more mixed than the headline suggests.[6]
The speed of the loss
The most consistent signal across every dataset. The more weight lost, and the faster, the more hair — 57.0% of those losing 40 pounds or more reported both shedding and thinning.[7]
Protein falling with appetite
These drugs work by reducing intake. Protein is often the first thing to drop, because it is the least appealing food when you are not hungry. One bariatric study found lower blood protein parameters in the patients who lost hair.[6]
Folate — the strongest association
Of the nutrients tested in the bariatric data, low folic acid had the firmest statistical link to hair loss, ahead of both ferritin and zinc.[6] It is also the one nobody mentions.
Ferritin
Significantly lower in those who lost hair (SMD −0.22, 95% CI −0.38 to −0.05).[6] Ferritin measures iron stores, which is a different test from serum iron — a distinction that matters below.
Zinc — probable, not proven
Lower zinc is usually listed as a cause, but in that analysis the result sat right on the line (SMD −1.13, 95% CI −2.27 to 0.01) and the interval crosses zero.[6] A trend worth acting on, not an established fact.
What was already there
Androgenetic alopecia diagnoses rose alongside telogen effluvium in the cohort data.[3] A shed does not create pattern loss, but it removes the density that was concealing it.
Two cautions from the same dataset. Serum iron showed no significant difference between bariatric patients who lost hair and those who did not — but its effect size was close to zinc's, with a much wider confidence interval, so this is weak evidence of nothing rather than strong evidence of no effect.[6] And low ferritin is genuinely common in women who shed: one single-center review of 2,851 women with telogen effluvium in Turkey found ferritin below range in 46.5% of those tested.[10] Common is not the same as causal, that study did not show that correcting it resolved the shedding, and a single-center figure is not a general prevalence. Iron in particular should be tested before it is taken rather than after, because excess iron is stored rather than excreted. Ask your prescriber which blood tests are worth running.
What Actually Helps
The 2026 systematic review is subtitled “implications for counseling,” and its recommendations are the most concrete guidance published so far. They are not dramatic, which is itself informative.[4]
Why Stopping the Medication Is the Wrong First Move
It is worth saying directly, because the internet says the opposite: never stop a prescribed medication on your own. These drugs are prescribed for type 2 diabetes and for obesity, both of which carry consequences considerably more serious than a temporary shed. The meta-analysis closes with the same instruction to clinicians — counsel proactively, optimize nutrition, and “avoid premature drug discontinuation.”[5]
The European regulator goes further, and it is the most reassuring line published on this so far. Its assessment of semaglutide records that the hair-loss events were mainly of mild severity and that most patients recovered while on continued treatment — that is, the hair came back without the medication being stopped.[16] The same assessment notes hair loss was reported more frequently in patients who lost the most weight,[16] which is the pattern this whole article describes.
The survey data is the useful counterweight. Among 504 users, 38.9% reported hair changes and 38.7% reported skin changes — and 92.0% still reported satisfaction with treatment, with 84.0% reporting improved body image.[7] People are, on the whole, weighing this correctly.
The published guidance reflects that proportion. The review suggests that in cases of severe shedding with significant distress, rapid excessive weight loss, or confirmed nutritional deficiency, dose adjustment or a temporary hold may be considered on an individualized basis.[4] Severe, distressing, or with a deficiency on paper — and decided with a clinician, case by case.
When It Isn't a Temporary Shed
Most of this resolves. The reason to have it looked at is the minority that does not, and the features that distinguish them are specific.
- It has run past six months with stable weight. Once the trigger has stopped, the clock should be running down. A shed lasting more than six months is classed as chronic telogen effluvium and deserves a different workup.[8]
- The part line is widening rather than the whole scalp thinning. Diffuse shedding is even. A widening part is a pattern, and patterns do not resolve on their own.
- The scalp hurts, burns or feels tender. Trichodynia — tenderness, pain, burning, itching or stinging — is a recognized symptom of telogen effluvium itself,[8] but pain alongside visible scalp changes is a reason to be examined rather than reassured.
- There are smooth, well-defined bald patches. That is not telogen effluvium. Notably, the meta-analysis found no significant association with alopecia areata (aOR 1.08, 95% CI 0.87–1.34),[5] and in the matched cohort it was actually more common in the controls.[3] Patches are a separate problem needing separate assessment.
- There is redness, scaling or scarring at the roots. Scarring hair loss destroys the follicle permanently, and the window to act on it is short.
One genuinely surprising finding, included because it cuts the other way. In the same meta-analysis, 58% of patients with central centrifugal cicatricial alopecia — a scarring hair loss — improved while taking GLP-1 receptor agonists.[5] The authors call it paradoxical, and it rests on a small number of patients within a synthesis rather than on a trial. It is not a reason to take these drugs for hair, and nobody should read it that way. It is a reason to be careful about the sentence “GLP-1s cause hair loss,” which is doing a lot of work that the evidence does not support.
Compared With Other Causes of Shedding
The GLP-1 column is the subject of this article. The others are the conditions it is most often confused with — including the seasonal shed, whose peak in resting-phase hairs was measured by trichogram in 823 women over six years and falls in summer, with a smaller second peak in spring.[12]
| Feature | GLP-1 associated shed | Seasonal shed | Female pattern loss | Post-bariatric shed |
|---|---|---|---|---|
| What starts it | Rapid weight loss and reduced intake | Follicles entering rest together, peaking in summer | Genetics and hormones over years | Rapid surgical weight loss |
| When it appears | 2 to 3 months after starting | Late summer into autumn | Gradual, no clear start date | Within the first months after surgery |
| Distribution | Diffuse, whole scalp | Diffuse, whole scalp | Widening part, crown | Diffuse, whole scalp |
| How long | Improves 3 to 6 months after weight stabilizes | Weeks to a few months | Progressive without treatment | Reports fall sharply after the first year |
| Does it reverse | Usually — no evidence of permanent follicle damage | Yes | No, but it can be slowed | Usually |
| What it responds to | Slower pace, protein and micronutrient adequacy | Time | Long-term medical management | Nutritional repletion |
What Happens at a Scalp Evaluation
A trichological evaluation is an assessment of the scalp and hair, not a medical diagnosis, and it does not replace the clinician managing your medication. What it does is turn an impression into a measurement.
Under magnification the scalp shows things a mirror cannot: the proportion of follicles producing one fine hair where there used to be several, the density per square centimeter in marked zones that can be measured again on the next visit, and whether there is inflammation or scaling at the root. Those numbers are what make a six-month comparison meaningful rather than a matter of memory.
One note on a test you may be offered elsewhere. The hair pull test has been revised: an evidence-based update concluded that normal values should be reduced to 2 hairs or fewer, and that the previous five-day restriction on washing the hair before the test can be relaxed.[11] Thresholds quoted from older sources are worth questioning.
The Evidence Behind This Article, Graded
Each claim, and how well it is actually supported.
Well established
Found independently by a target trial emulation using active drug comparators,[2] by two large matched cohorts,[3][18] in placebo-controlled trial adverse-event data,[4] and in a meta-analysis restricted to interventional studies, most of them randomized.[17] It is also recorded in the FDA prescribing information for both obesity drugs.[13][14] Four different designs, four different weaknesses, same direction.
Well supported, with a stated limit
The published review finds no strong evidence of permanent follicular damage and describes the cases as resembling telogen effluvium, typically self-limited and reversible.[4] The limit: follow-up in these datasets is twelve months or less, and the BMJ authors say plainly they could not assess severity, duration or reversibility at all.[2] “Reversible” is supported over that window, not over a decade.
Well established, and long predates these drugs
18 studies and 2,538 bariatric surgery patients, pooled hair loss 57% (95% CI 42–71%).[6] No GLP-1 involved.
The leading explanation, not a proven one
It is the stated conclusion of the meta-analysis[5] and of the BMJ investigators,[2] and the weight-response and comparator patterns fit it.[7][9] But no trial has randomized people to equivalent weight loss with and without the drug, which is what would settle it. A direct follicular effect has not been excluded. And one large study argues against this reading: a cohort of 576,250 matched pairs found androgenetic alopecia risk rising to 2.41-fold over time, and its authors state that the BMI reductions they observed were modest, “suggesting that the risk of hair loss may not be fully explained by rapid or extreme weight loss alone.”[18] That is a direct challenge to the mechanism described here, and it is why this claim is graded as leading rather than settled.
Not supported
The pooled adjusted odds ratio was 1.08 with a confidence interval of 0.87 to 1.34, which crosses 1.[5] In the matched cohort, alopecia areata was more common in the controls.[3] Included here because it is the kind of claim that circulates anyway.
Weaker than it is usually presented
In the bariatric data the zinc result sat on the significance boundary with a confidence interval crossing zero, and serum iron — reported as a null finding — had a similar effect size with a wider interval.[6] Folic acid had the firmest association of the nutrients tested, and it is the one nobody writes about.
The honest gaps
No study has compared GLP-1 users against people losing weight at the same rate by other means. Several large datasets identify hair loss through diagnostic coding rather than examination, which records who sought care rather than who shed.[3] The meta-analysis's headline odds ratio rests on three cohort studies, not seventeen, and its telogen effluvium and androgenetic alopecia figures come from one of them.[5][3] The patient survey quoted here was conducted by employees of a cosmetics manufacturer, which is disclosed in the paper and is relevant to how its quality-of-life findings are read.[7] And to be explicit: no controlled trial of any Kapyderm product in GLP-1 associated shedding exists. Nothing here should be read as a claim that a cosmetic product treats drug-associated hair loss.
Frequently Asked Questions
- American Academy of Dermatology Association. “Do you have hair loss or hair shedding?” aad.org. Clinical reference for normal daily shedding of 50 to 100 hairs, telogen effluvium, and the six-to-nine-month return to normal fullness.
- Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. The BMJ. 2026;394:e100077. doi:10.1136/bmj-2026-100077. University of Pennsylvania Health System records, January 2019 to September 2024; GLP-1 users compared against SGLT-2 inhibitor and DPP-4 inhibitor users.
- Vidal SI, Akiska YM, Nasseri M, et al. Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TriNetX cohort study. JAAD International. 2026;25:133–135. doi:10.1016/j.jdin.2026.01.014. Research letter. 547,993 matched adults, 67 US healthcare organizations, 2014–2024; outcomes identified from ICD-10 codes.
- Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress. 2026;109(2). doi:10.1177/00368504261444578. 24 of 133 screened studies included.
- Viquez Burboa GU, Flores Guillén MAR, Duardo González VS. GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disorders. 2026. doi:10.1159/000553070. 17 studies, 1,091,743 patient-exposures; PROSPERO CRD420261335458. The pooled odds ratio for non-scarring alopecia derives from three cohort studies.
- Zhang W, Fan M, Wang C, Mahawar K, Parmar C, Chen W, Yang W. Hair Loss After Metabolic and Bariatric Surgery: a Systematic Review and Meta-analysis. Obesity Surgery. 2021;31(6):2649–2659. doi:10.1007/s11695-021-05311-2. 18 studies, 2,538 patients.
- Olivero JW, Paturi J, Moreau M, et al. Dermatological, Trichological and Quality of Life Consequences of GLP-1 Receptor Agonist-Mediated Weight Loss: A US Cross-Sectional Survey. Journal of Cosmetic Dermatology. 2026;25(8):e71145. doi:10.1111/jocd.71145. 504 respondents, self-reported, geographically concentrated. The authors disclose that they are employees of a cosmetics manufacturer.
- Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020;12(5):e8320. Reference for the telogen phase duration, the two-to-three-month lag after a trigger, trichodynia, and the definition of chronic telogen effluvium.
- Fang X, Li R, Liu S, Zou X, Zhong Y, Yang Y. SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes. Frontiers in Endocrinology. 2026;17:1930813. doi:10.3389/fendo.2026.1930813. Cited for the weight difference between the two comparator drug classes used in reference 2.
- Karakoyun Ö, Ayhan E, Yıldız İ. Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience. Journal of Cosmetic Dermatology. 2025;24(2):e70037. doi:10.1111/jocd.70037. Single center, Dicle University, Turkey.
- McDonald KA, Shelley AJ, Colantonio S, Beecker J. Hair pull test: Evidence-based update and revision of guidelines. Journal of the American Academy of Dermatology. 2017;76(3):472–477. Concludes normal values should be reduced to 2 hairs or fewer.
- Kunz M, Seifert B, Trüeb RM. Seasonality of hair shedding in healthy women complaining of hair loss. Dermatology. 2009;219(2):105–110. 823 women, six years of trichograms; cited here for the seasonal comparison only.
- WEGOVY (semaglutide) injection, for subcutaneous use. US Prescribing Information, Novo Nordisk. Revised June 2026, section 6.1. Accessed via DailyMed. Hair loss 3% vs 1% placebo at 2.4 mg; 5.8% vs 1.0% at 7.2 mg; 8.4% of women vs 0.2% of men at 7.2 mg; 4% vs 0% in patients aged 12 and over.
- ZEPBOUND (tirzepatide) injection, for subcutaneous use. US Prescribing Information, Eli Lilly. Revised 28 August 2026, section 6.1. Accessed via DailyMed. Hair loss 5% (5 mg), 4% (10 mg) and 5% (15 mg) vs 1% placebo; 7.1% of women vs 0.5% of men.
- OZEMPIC (semaglutide) injection, US Prescribing Information, Novo Nordisk, revised May 2026, section 6.2; and MOUNJARO (tirzepatide) injection, US Prescribing Information, Eli Lilly, revised 27 August 2026, section 6.2. Both accessed via DailyMed. In both labels alopecia appears under Postmarketing Experience only, with no clinical-trial incidence rate reported.
- Wegovy Summary of Product Characteristics, section 4.8. European Medicines Agency. Hair loss listed as Common; 2.5% vs 1.0% placebo, and 5.3% at 7.2 mg. States that the events were mainly of mild severity, that most patients recovered while on continued treatment, and that hair loss was reported more frequently in patients with greater weight loss.
- Cheng P-L, Chang H-C. Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2026;237:113333. doi:10.1016/j.diabres.2026.113333. Nine interventional studies, seven of them randomized controlled trials, 4,114 GLP-1 users.
- Herrera HO, Bordeaux JS. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology. 2026;94:1826–1827. doi:10.1016/j.jaad.2026.02.042. 576,250 propensity-matched pairs against metformin-only controls.
This article draws on one target trial emulation, four systematic reviews with meta-analysis — one of them restricted to interventional studies — a further systematic review, two real-world matched cohorts, one cross-sectional patient survey, one single-center retrospective review, the FDA prescribing information for all four drugs and the European regulator's assessment, three further peer-reviewed clinical papers and one clinical reference body. Every figure quoted was read at its source, and where a number comes from a single study inside a larger review, that is stated. No controlled trial of any Kapyderm product in GLP-1 associated hair shedding exists, and none is implied.
Most of This Shedding Stops.
Knowing Which Kind You Have Is the Point.
If your shedding has run past six months with stable weight, if your part is widening rather than the whole scalp thinning, or if the scalp burns or feels tender, that is worth an evaluation rather than another product. Our specialists assess the scalp under magnification, record the numbers so the next visit has something to compare against, and refer to a physician when that is what the picture calls for.
